CODX Profile
Co-Diagnostics, Inc., based in Salt Lake City, Utah, is a leading molecular diagnostics company specializing in the development, manufacture, and sale of reagents for diagnostic tests. These tests are primarily focused on detecting and analyzing nucleic acid molecules, offering critical solutions for various infectious diseases and other health conditions. The company operates both domestically and internationally, providing a wide range of diagnostic tools and technologies.
The company’s product portfolio includes a diverse array of polymerase chain reaction (PCR) diagnostic tests. These tests are designed to detect pathogens and viruses such as COVID-19, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and Zika virus. Additionally, Co-Diagnostics offers multiplexed tests specifically for identifying diseases transmitted by mosquitoes, enhancing the ability to monitor and control vector-borne diseases.
Co-Diagnostics also develops molecular tools aimed at various applications, including liquid biopsy for cancer screening, agricultural diagnostics, and genetic trait identification in plant and animal genomes. Their innovations extend to portable PCR devices, which facilitate point-of-care testing and at-home diagnostics, thereby increasing accessibility to accurate and timely medical testing.
In addition to its core product offerings, the company plans to expand its portfolio by incorporating diagnostic equipment from other manufacturers, aiming to provide self-contained lab systems. Founded in 2013, Co-Diagnostics has established itself as a key player in the molecular diagnostics field, leveraging its advanced technology and extensive product range to meet the evolving needs of the healthcare and agricultural sectors.
|
